
USD
$0.00
(0.00%
)At Close (As of Oct 24, 2025)
$3.14B
Market Cap
-
P/E Ratio
-3.55
EPS
$46.00
52 Week High
$26.74
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$2.6M |
| Total Revenue | $0 |
| Cost Of Revenue | $2.6M |
| Costof Goods And Services Sold | $2.6M |
| Operating Income | -$279M |
| Selling General And Administrative | $69M |
| Research And Development | $210M |
| Operating Expenses | $277M |
| Investment Income Net | - |
| Net Interest Income | $42M |
| Interest Income | $42M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.6M |
| Income Before Tax | -$238M |
| Income Tax Expense | -$4.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$234M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$238M |
| Ebitda | -$236M |
| Net Income | -$234M |
| Field | Value (USD) |
|---|---|
| Total Assets | $798M |
| Total Current Assets | $635M |
| Cash And Cash Equivalents At Carrying Value | $143M |
| Cash And Short Term Investments | $143M |
| Inventory | - |
| Current Net Receivables | $1.5M |
| Total Non Current Assets | $163M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $127M |
| Short Term Investments | $484M |
| Other Current Assets | $6.9M |
| Other Non Current Assets | - |
| Total Liabilities | $43M |
| Total Current Liabilities | $36M |
| Current Accounts Payable | $5.1M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $10M |
| Total Non Current Liabilities | $7.6M |
| Capital Lease Obligations | $9M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $9M |
| Other Current Liabilities | $14M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $755M |
| Treasury Stock | - |
| Retained Earnings | -$899M |
| Common Stock | $1.5B |
| Common Stock Shares Outstanding | $78M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$181M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.6M |
| Capital Expenditures | $3.1M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $165M |
| Cashflow From Financing | $12M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$234M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$2.6M |
| Total Revenue | $0 |
| Cost Of Revenue | $2.6M |
| Costof Goods And Services Sold | $2.6M |
| Operating Income | -$279M |
| Selling General And Administrative | $69M |
| Research And Development | $210M |
| Operating Expenses | $277M |
| Investment Income Net | - |
| Net Interest Income | $42M |
| Interest Income | $42M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.6M |
| Income Before Tax | -$238M |
| Income Tax Expense | -$4.1M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$234M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$238M |
| Ebitda | -$236M |
| Net Income | -$234M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Burnaby, Canada, dedicated to pioneering innovative therapies for neurological disorders. With a diverse and promising pipeline of drug candidates, the company utilizes cutting-edge technologies to address genetic and rare conditions, significantly enhancing patient care and treatment options. Xenon's unwavering commitment to scientific rigor and patient-centric outcomes underscores its strategic positioning within the biopharmaceutical sector, as it seeks to make impactful contributions in both national and international healthcare markets.